Literature DB >> 19471637

Gemcitabine more useful.

Michael Geibler.   

Abstract

Entities:  

Year:  2008        PMID: 19471637      PMCID: PMC2680577          DOI: 10.3238/arztebl.2008.0655

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

2.  [S3-Guidelines "Exocrine pancreatic cancer" 2007].

Authors:  G Adler; T Seufferlein; S C Bischoff; H-J Brambs; S Feuerbach; G Grabenbauer; S Hahn; V Heinemann; W Hohenberger; J M Langrehr; M P Lutz; O Micke; H Neuhaus; P Neuhaus; H Oettle; P M Schlag; R Schmid; W Schmiegel; K Schlottmann; J Werner; B Wiedenmann; I Kopp
Journal:  Z Gastroenterol       Date:  2007-06       Impact factor: 2.000

3.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

4.  Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.

Authors:  D D Stocken; M W Büchler; C Dervenis; C Bassi; H Jeekel; J H G Klinkenbijl; K E Bakkevold; T Takada; H Amano; J P Neoptolemos
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.